Trial
Trial Tuesday: The data almost cooperated. Almost.
Here is a thought experiment: where would we be if the FDA and other regulators did not allow trial flexibility? Keytruda, still the world's best-selling drug, got its initial US approval on a surrogate endpoint. Without that flexibility, it reaches the market at least a year later, and